Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Oncology Reviews Could Remain Split After CBER/CDER Reorganization

Nov 25 2002

• By The Pink Sheet

Related Content

CBER/CDER Consolidation Working Group Set To Meet Week Of Sept. 16

Sep 09 2002

Erbitux Oncologic Potential Endorsed By FDA, Bristol During House Hearing

Jun 17 2002

CBER Reorganization Will Proceed Without Siegel; OTRR Director To Retire

Nov 18 2002

FDA Commissioner McClellan Sworn-In; First Focus Is Employee Morale

Nov 18 2002

FDA Emphasizing Written Communication With Sponsors On Pending NDAs

Oct 14 2002

CBER/CDER Reorganization: Product Transfer Set, Resources Under Review

Nov 04 2002

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window